ArticleThe New England journal of medicine2018
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations; Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
No numbers read from the abstract.
4 papers cite it
this papercites it